Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge

Clinical Infectious Diseases

Volumn 42, Issue 9, 2006, Pages 1283-1288

  Taylor, David N ^a,b   McKenzie, Robin ^a   Durbin, Anna ^a   Carpenter, Colleen ^a   Atzinger, Christophe B ^a   Haake, Robert ^b   Bourgeois, A Louis ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BICARBONATE; CIPROFLOXACIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PLACEBO; RIFAXIMIN;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSENTERY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHIGELLA FLEXNERI; SHIGELLOSIS; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; DOUBLE-BLIND METHOD; DYSENTERY, BACILLARY; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; RIFAMYCINS; TIME FACTORS;

EID: 33646076468     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/503039     Document Type: Article

References (26)

1. Brewster SJ, Taylor DN. Epidemiology of travelers' diarrhea. In: Keystone JS, Kozarsky PE, Freedman DO, Nothdurft HD, Connor BA, eds. Travel medicine. 1st ed. New York: Mosby, Elsevier Limited, 2004: 175-84.
2. Steffen R, Tornieporth N, Costa Clemens SA, et al. Epidemiology of travelers' diarrhea: details of a global survey. J Travel Med 2004; 11: 231-8.
3. Steffen R. Epidemiologic studies of travelers' diarrhea, severe gastrointestinal infections, and cholera. Rev Infect Dis 1986;8(suppl 2): S122-30.
4. Rees JR, Pannier MA, McNees A, et al. Persistent diarrhea, arthritis, and other complications of enteric infections: a pilot survey based on California FoodNet surveillance, 1998-1999. Clin Infect Dis 2004; 38(suppl 3):S311-7.
5. Rees JH, Soudain SE, Gregson NA, et al. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995; 333:1374-9.
6. Taylor DN, Connor BA, Shlim DR. Chronic diarrhea in the returned traveler. Med Clin North Am 1999; 83:1033-52.
7. Okhuysen PC, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99:1774-8.
8. Peltola H, Gorbach SL. Travelers' diarrhea. Epidemiology and clinical aspects. In: DuPont HL, Steffen R, eds. Textbook of travel medicine and health. 2nd ed. Hamilton, Canada: BC Decker, 2001:151-83.
9. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin Infect Dis 2002; 34:628-33.
10. Ericsson CD. Travelers' diarrhoea. Int J Antimicrob Agents 2003; 21: 116-24.
11. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003; 98:1073-8.
12. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal gram-negative flora and enterococci. Clin Microbiol Infect 2004; 10:1009-11.
13. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33:1807-15.
14. DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: an unabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion 1998; 59:708-14.
15. DuPont HL, Jiang ZD, Okhuysen P, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005; 142:805-12.
16. Phalipon A, Sansonetti PJ. Shigellosis: innate mechanisms of inflammatory destruction of the intestinal epithelium, adaptive immune response, and vaccine development. Crit Rev Immunol 2003; 23:371-101.
17. Taylor DN. Poorly absorbed antibiotics for the treatment of traveler's diarrhea. Clin Infect Dis 2005;41(Suppl 8):S564-70.
18. DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 1989; 159:1126-8.
19. Coster TS, Hoge CW, VanDeVerg LL, et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999; 67:3437-13.
20. Jennison AV, Verma NK. Shigella flexneri infection: pathogenesis and vaccine development. FEMS Microbiol Rev 2004; 28:43-58.
21. Shanks GD, Ragama OB, Aleman GM, et al. Azithromycin prophylaxis prevents epidemic dysentery. Trans R Soc Trop Med Hyg 1996; 90:316.
22. Ben-Yehuda O, Cohen D, Alkan M, et al. Doxycycline prophylaxis for shigellosis. Arch Intern Med 1990; 150:209-12.
23. Ericsson CD, Kollaritsch H. Prophylactic use of drugs. In: DuPont HL, Steffen R, eds. Textbook of travel medicine and health. 2nd ed. Hamilton, Canada: BC Decker, 2001:160-74.
24. Gupta A, Polyak CS, Bishop RD, Sobel J, Mintz ED. Laboratory-confirmed shigellosis in the United States, 1989-2002: epidemiologic trends and patterns. Clin Infect Dis 2004; 38:1372-7.
25. Mahoney FJ, Farley TA, Burbank DF, Leslie NH, McFarland LM. Evaluation of an intervention program for the control of an outbreak of shigellosis among institutionalized persons. J Infect Dis 1993; 168: 1177-80.
26. Mahoney FJ, Farley TA, Moriniere BJ, Winsor DK, Silberman RL, McFarland LM. Evaluation of an intervention program in the control of an urban outbreak of shigellosis. Am J Prev Med 1991; 7:292-7.